Q-linea AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-1.75.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-19.47.
During the past 3 years, the average EBIT per Share Growth Rate was 71.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 50.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Q-linea AB's EBIT per Share or its related term are showing as below:
CHIX:QLINEs'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.2 Med: 2.2 Max: 71.9
Current: 71.9
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Q-linea AB was 71.90% per year. The lowest was -45.20% per year. And the median was 2.20% per year.
CHIX:QLINEs's 3-Year EBIT Growth Rate is ranked better than 94.93% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs CHIX:QLINEs: 71.90
Q-linea AB's EBIT for the
three
months ended in Mar. 2026 was kr-33.16 Mil.
Q-linea AB (CHIX:QLINEs) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Q-linea AB EBIT per Share Related Terms
Q-linea AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Q-linea AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-19.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a EBIT per Share of kr-19.47 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #35 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 5.1%.
Is Q-linea AB's EBIT per Share too high?
Q-linea AB's current EBIT per Share is kr-19.47. Based on the distribution chart, Q-linea AB ranks #35 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #35 out of 690 companies for EBIT per Share. This places Q-linea AB in the top 5% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current EBIT per Share is kr-19.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current EBIT per Share of kr-19.47. The stock's GF Value™ is kr1,981.69, compared to a current price of kr1,610.00 — trading 18.8% below its estimated fair value. The current EBIT per Share is kr-19.47. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current EBIT per Share is kr-19.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 18.8% below its estimated GF Value™ of kr1,981.69.
Key valuation signals for CHIX:QLINES:
EBIT per Share: kr-19.47
GF Value™: kr1,981.69 vs. price of kr1,610.00 (18.8% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score
Get the complete analysis for CHIX:QLINES
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
